NCT04657211Completed
Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants
Triple thErapy in paTients With COPD Under Real lIve Setting (the TETRIS Study)
Source: ClinicalTrials.gov · Last updated 17 Aug 2025
Brief summary (registry, in English)
TETRIS is a multi-center, prospective observational cohort study. It will include participants with COPD who are on an existing combined treatment of long-acting muscarinic antagonist (LAMA), long-acting beta 2 agonists (LABA) and inhaled corticosteroids (ICS).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1212 (actual)
- First submitted
- 1 Dec 2020
- Start date
- 14 Jan 2021
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- GlaxoSmithKline
- Diseases
- COPD
- NCT number
- NCT04657211
What you commit to
- Study type: Observational
- Participants enrolled: 1212
- From 14 Jan 2021 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participant is currently enrolled or has participated in a study within the last 90 days before signing of consent involving investigational study treatment intervention. If, while enrolled in the present study, the participant enrolls in another study involving investigational study treatment intervention, he/she will be withdrawn from the present study.
Other illness
- Participant has a current diagnosis of lung cancer or lung metastasis.
- Participant has a current primary diagnosis of diffuse pan-bronchiolitis, or a primary diagnosis of bronchiectasis or pulmonary fibrosis or cystic fibrosis or other significant respiratory disorders.
- Recent (\<= months) major cardiac or pulmonary event (for example myocardial infarction, pulmonary embolism).
Other
- Participant has a diagnosis of pure asthma, without clinical features of COPD.
Who the study is looking for
- Participant is at least 18 years of age at the time of signing the informed consent.
- Participant is on a SITT or MITT for treatment of an obstructive respiratory disease for a period of 6 to 18 weeks prior enrolment with a combination of inhaled LAMA, LABA and ICS either on a triple maintenance treatment or an intermediate triple therapy regime (ICS "on/off" or LAMA "on/off").
- Inclusion criteria for Group A- (treatment by settled general practitioners): Participants are treated according to a physicians diagnosis of COPD.
- Inclusion criteria for Group B and C- (treatment by settled pulmonologists or treatment by outpatient lung centers): Participants have a confirmed physician's diagnosis (diagnosis based on spirometry or body plethysmography) of COPD.
- Participants need to give and be capable of giving signed informed consent form (ICF).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Hanover | Germany | Unknown status |
Related publications
- A multicentre, observational prospective study to characterise the use of inhaled triple therapy for COPD: TETRIS final results after a 24-month follow-up period.Ther Adv Respir Dis · 2026 · PMID 42710849
- TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis.Respir Med · 2026 · PMID 41418889
This page is information, not medical advice. Discuss any trial with your doctor.